AMGEN (AMGN)

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Company profile

Ticker

AMGN

Exchange

NASDAQ

Website

www.amgen.com

CEO

Robert Bradway

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics • Allogene Therapeutics ...

Former names

AMGEN

SEC CIK

0000318154

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Amgen (Europe) GmbH • Amgen Canada Inc. • Amgen Fremont Inc. • Amgen Global Finance B.V. • Amgen GmbH • Amgen Ilaç Ticaret Limited • Amgen K-A, Inc. • Amgen Manufacturing, Limited • Amgen Research (Munich) GmbH • Amgen Rockville, Inc. ...

IRS number

953540776

AMGN stock data

1M 1Y 5Y

News

From Benzinga Pro

Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock

9 Aug 22

Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading.

Atlantic Equities Maintains Underweight on Amgen, Lowers Price Target to $182

9 Aug 22

Atlantic Equities analyst Steve Chesney maintains Amgen (NASDAQ:AMGN) with a Underweight and lowers the price target from $190 to $182.

Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern

8 Aug 22

Analyst Ratings for Amgen

5 Aug 22

Amgen's Q2 Sales Impacted By Lower Prices, Currency Headwind, Reaffirms FY22 Outlook

5 Aug 22

Press releases

From Benzinga Pro

AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022

8 Aug 22

Phase 1 Tarlatamab Study Showed Encouraging Antitumor Activity With Median Duration of Response of 13 Months in Small Cell Lung Cancer No Approved Treatment Options Available to Patients in Third-line Setting THOUSAND

CHEMOCENTRYX, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of CCXI and Encourages Investors to Contact the Firm

7 Aug 22

NEW YORK, Aug. 07, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of ChemoCentryx,

AMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS

7 Aug 22

First Data From LUMAKRAS Plus Immunotherapy and LUMAKRAS Plus SHP2 Inhibitor Combinations Show Clinical Activity and Support Ongoing Investigation Updated Phase 1 Tarlatamab Data Reinforce Potential of BiTE®

SHAREHOLDER ALERT: Weiss Law Investigates ChemoCentryx, Inc

4 Aug 22

AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS

4 Aug 22

Analyst ratings and price targets

Last 3 months

Average target

$251.33

Low target

$208.00

High target

$290.00

Mizuho

Maintains

Neutral

$208.00

10 May 22

Calendar

4 Aug 22

9 Aug 22

31 Dec 22

Financial summary

Financial statements Chart AMGN financial data

Quarter (USD)	Jun 22	Mar 22	Dec 21	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	5.2B	5.2B	5.2B	5.2B	5.2B	5.2B
Cash burn (monthly)	441.67M	118.92M	(no burn)	(no burn)	(no burn)	(no burn)
Cash used (since last report)	591.96M	159.38M	n/a	n/a	n/a	n/a
Cash remaining	4.61B	5.04B	n/a	n/a	n/a	n/a
Runway (months of cash)	10.4	42.4	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from AMGEN earnings reports.

Recent insider trades

AMGN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
31 Jul 22	Nancy A. Grygiel	Common Stock	Payment of exercise	Dispose F	No	No	247.47	1,229	304.14K	13,728
31 Jul 22	Rachna Khosla	Common Stock	Payment of exercise	Dispose F	No	No	247.47	217	53.7K	7,158
23 May 22	Williams R Sanders	Common Stock	Sell	Dispose S	No	Yes	250	600	150K	5,501
17 May 22	Austin Wanda M	Common Stock	Grant	Acquire A	No	No	0	855	0	4,886

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

AMGN institutional ownership history Ownership history

78.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2258	2229	+1.3%
Opened positions	172	297	-42.1%
Closed positions	143	155	-7.7%
Increased positions	946	846	+11.8%
Reduced positions	804	829	-3.0%

13F shares	Current	Prev Q	Change
Total value	100.77B	94.99B	+6.1%
Total shares	418.74M	422.56M	-0.9%
Total puts	7.53M	3.96M	+89.9%
Total calls	7.01M	3.88M	+80.8%
Total put/call ratio	1.1	1.0	+5.0%

Largest owners	Shares	Value	Change
BLK Blackrock	50.03M	$12.1B	-0.0%
Vanguard	47.33M	$11.45B	+1.4%
STT State Street	30.5M	$7.38B	+1.2%
Capital Research Global Investors	18.43M	$4.46B	-16.8%
Primecap Management	15.73M	$3.8B	-0.3%
MS Morgan Stanley	14.43M	$3.49B	+49.3%
Geode Capital Management	10.8M	$2.61B	+5.6%
Charles Schwab Investment Management	8.82M	$2.13B	+1.1%
NTRS Northern Trust	7.63M	$1.85B	-0.6%
WFC Wells Fargo & Co.	7.61M	$1.84B	+14.2%

Largest transactions	Shares	Bought/sold	Change
Norges Bank	0	-5.06M	EXIT
MS Morgan Stanley	14.43M	+4.77M	+49.3%
Capital Research Global Investors	18.43M	-3.73M	-16.8%
JPM JPMorgan Chase & Co.	5.61M	+2.02M	+56.1%
Capital International Investors	634.99K	-1.95M	-75.5%
BCS Barclays	1.26M	-1.77M	-58.3%
CFS Investment Advisory Services	1.27M	+1.27M	+24077.4%
BAC Bank Of America	7.19M	+1.25M	+21.1%
GS Goldman Sachs	2.56M	-1.04M	-28.8%
Healthcare Of Ontario Pension Plan Trust Fund	1.24K	-958.25K	-99.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Celgene • ImmunoCellular Therapeutics • Novelion Therapeutics • Spectrum Pharmaceuticals • Mosaic ImmunoEngineering • ARIAD Pharmaceuticals • Geron • Roche • Nektar Therapeutics • FibroGen

Management Discussion

Future sales of our products will depend in part on the factors discussed below and in the following sections of this report: (i) Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview, and Selected Financial Information; and (ii) Part II, Item 1A. Risk Factors, and in the following sections of our Annual Report on Form 10-K for the year ended December 31, 2021: (i) Part I, Item 1. Business—Marketing, Distribution and Selected Marketed Products; (ii) Part I, Item 1A. Risk Factors; and (iii) Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview, and Results of Operations—Product Sales, as well as in our Quarterly Report on Form 10-Q for the period ended March 31, 2022: (i) Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations—Product Sales; and (ii) Part II, Item 1A. Risk Factors.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abandoning, AbbVie, adapted, added, adding, adjunctive, Advantage, Alzheimer, ANCA, argued, ASCVD, AVSOLA, awaiting, ballot, benchmark, Bergamo, biennial, body, broader, burden, burdensome, ceiling, certainty, ChemoCentryx, chosen, classified, coinsurance, complaint, component, constitutionality, contravention, Corlanor, CVS, cytoplasmic, de, deeper, discarded, divert, divestiture, dose, downstream, Dusseldorf, EIS, evolution, facto, familial, Finansal, Florida, formulary, Gensenta, Hampshire, HoFH, hypercholesterolemia, IMLYGIC, impede, improperly, inadequately, incremental, inflammatory, inhaled, inhibitor, inquiry, intensified, interference, interfering, interlocutory, IRP, jeopardize, la, launched, lawsuit, leverage, lieu, list, listed, losing, Maine, maintenance, marketplace, Mexico, nondeductible, nonstrategic, older, olpasiran, oppose, Orange, Oregon, outlined, permission, placement, plc, pleading, prejudice, pressure, pretax, proliferation, proportion, prostate, receptor, recommended, refine, refuse, repeal, restructuring, RIABNI, RNA, role, Sanayi, SAS, saving, siRNA, small, sought, standing, subcutaneously, suit, Ticaret, timeframe, top, topline, translation, Turkey, Turkish, unanticipated, unfair, unilaterally, upheld, usage, ve, Vermont, waived, Washington, week, withholding

Removed: al, amplify, build, collection, conduct, continuously, cybersecurity, decision, duration, EBITDA, emerging, evolving, home, Hospira, infection, inter, internationally, interrupted, iv, local, meaningful, oral, precipitate, privacy, protect, protection, referencing, relating, reliance, sell, spread, stemming, submit, succeed, transmission, vaccination, vulnerable, wide

From filing 10-Q 2022 Q2

Financial reports

View all